Christopher Paris, MD
Interventional Cardiology · Luling, LANPI 1902953888
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (30.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 29.7% of the total. Reporting peaked in 2019 at $16,754 and has fallen 96.7% since, to $546 in 2025.
Across 355 payments — averaging $103.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$11K
- Cardiovascular Systems Inc.$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Medtronic$4K
- Inari Medical, Inc.$3K
- Abiomed$1K
- plus $5K from 32 others
What the payments were for
- Consulting fees$10,92530%
- Speaking & faculty fees$10,47029%
- Travel & lodging$3,97811%
- Food & beverage$11,09730%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 32 | $10,849 |
| Cardiovascular Systems Inc. | 40 | $8,989 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $4,022 |
| Medtronic(2 entities) | 33 | $3,756 |
| Inari Medical, Inc. | 10 | $3,040 |
| Abiomed | 15 | $1,129 |
| Abbott | 16 | $800 |
| Novartis | 26 | $611 |
| Amgen | 50 | $447 |
| AstraZeneca | 22 | $401 |
| Penumbra, Inc. | 3 | $284 |
| Johnson & Johnson | 16 | $244 |
| Cardiva Medical, Inc. | 6 | $232 |
| Pfizer | 13 | $228 |
| Imperative Care, Inc | 2 | $190 |
| Esperion Therapeutics, Inc. | 6 | $110 |
| Cvrx, Inc. | 2 | $103 |
| GSK | 5 | $103 |
| Livanova USA, Inc. | 1 | $99 |
| Merck | 6 | $98 |
| Boehringer Ingelheim | 4 | $87 |
| Philips North America LLC | 2 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Angiodynamics, Inc. | 1 | $72 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Novo Nordisk | 3 | $64 |
| Boston Scientific | 3 | $55 |
| Terumo Medical Corporation | 3 | $46 |
| Bayer | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Itamar Medical Inc | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Biotronik Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| EKOS Corporation | 1 | $20 |
| Cook Medical LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coronary Orbital Atherectomy System$4,340
- Peripheral Orbital Atherectomy System$3,905
- LifeVest$3,850
- FlowTriever$2,762
- ClotTriever$2,762
- HawkOne$1,629
- CROSSER$924
- Impella$810
- Resolute$517
- Diamondback Coronary$383
- Indigo System$228
- RESOLUTE ONYX$226
- FLOWTRIEVER CATHETER, S$176
- CT THROMBECTOMY SYSTEM KIT$176
- CardioMEMS HF System$174
- COREVALVE EVOLUT R$162
- Claria MRI$156
- PRODIGY CATHETER$145
- Vascular Closure Device$127
- ULTRASCORE$126
How this compares
$36,570 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 480 | $492,025 |
| Repatha SureclickEvolocumab | 285 | $237,348 |
| XareltoRivaroxaban | 200 | $186,160 |
| MounjaroTirzepatide | 105 | $157,638 |
| OzempicSemaglutide | 45 | $58,217 |
| EntrestoSacubitril/Valsartan | 53 | $55,561 |
| FarxigaDapagliflozin Propanediol | 53 | $46,898 |
| JardianceEmpagliflozin | 58 | $45,236 |
| Praluent PenAlirocumab | 32 | $18,224 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,070 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,853 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,200 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,554 |
| VascepaIcosapent Ethyl | 13 | $7,278 |
| Metoprolol Succinate | 574 | $6,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $228 | $492,025480 claims |
| Johnson & JohnsonXarelto | $244 | $186,160200 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $401 | $71,168106 claims |
| Novo NordiskOzempic | $64 | $58,21745 claims |
| NovartisEntresto | $611 | $55,56153 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $87 | $52,79069 claims |
| GSKTrelegy Ellipta | $103 | $11,85318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Luling
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
- Jorge CastellanosBaton Rouge$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.